Danish pharmaceutical company Novo Nordisk B A/S (NOV.DE,NOVOB.CO,NVO) and German biomedical research institute BioMed X Tuesday announced a new collaboration to create effective oral delivery methods for therapeutic peptides. To tackle this issue, BioMed X and Novo Nordisk will establish a joint research team dedicated to advancing next-generation peptide formulations.
According to BioMed X, the project, titled "Prolonged Retention of Oral Peptide Formulations in the Gut", will be hosted at the company's Heidelberg campus. Its goal is to develop innovative oral formulation technologies capable of achieving site-specific, prolonged retention of tablets or capsules in the lower small intestine. The new research team will become part of the wider BioMed X research community in Heidelberg.
BioMed X said that current oral peptide formulations are limited by poor intestinal permeability and rapid gastrointestinal transit and such innovations would enable continuous drug release and efficient absorption while preserving gastrointestinal safety, and ultimately improving the patient's health.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.